Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.54 |
| ▸ | HRAS | P01112 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5677297 | 0.90 | ITGB3 (0.64) | ITGB3ITGA2BHDAC2 | |
| SCHEMBL5889527 | 0.87 | HRAS (0.61) | ITGB3ITGA2BHRASESR1ESR2 | |
| SCHEMBL5897339 | 0.85 | HRAS (0.48) | ITGB3ITGA2BHRASESR1ESR2 | |
| SCHEMBL7255843 | 0.84 | ITGB3 (0.63) | ITGB3ITGA2B | |
| SCHEMBL5677265 | 0.84 | ITGB3 (0.54) | ITGB3ITGA2BHDAC2NHERF1 | |
| SCHEMBL5680387 | 0.84 | ITGB3 (0.64) | ITGB3ITGA2BHDAC2NHERF1 | |
| SCHEMBL5889622 | 0.83 | ITGB3 (0.53) | ITGB3ITGA2BHRASESR1ESR2 | |
| SCHEMBL5889839 | 0.83 | HDAC2 (0.56) | ITGB3ITGA2BHDAC2NHERF1MAOA | |
| SCHEMBL5897020 | 0.83 | ITGB3 (0.60) | ITGB3ITGA2BHRASESR1ESR2 | |
| SCHEMBL5889938 | 0.82 | ITGB3 (0.49) | ITGB3ITGA2BHRASESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | claimed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | claimed |
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | disclosed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | ZC3HAV1, TYR, ZC3HAV1L | ITGB3 4436/4885ITGA2B 4759/4885HRAS 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.